Novo Nordisk, the Danish pharmaceutical giant behind Ozempic, is suing Eli Lilly for what it calls deliberately deceptive advertising of competing weight-loss treatments Zepbound and Mounjaro.
The lawsuit centers on claims that Eli Lilly cherry-picked outdated clinical data to make its drugs appear superior. Novo Nordisk alleges the rival company intentionally compared its highest-dose formulations against lower doses of Novo Nordisk's semaglutide, then presented these skewed results as proof of overall product dominance.
"Healthcare companies have a responsibility to keep their public claims accurate and current," said John F Kuckelman, Novo Nordisk's general counsel. "Ineffective, fine-print disclaimers do not fix the misleading impression created by major national campaigns."
The advertising campaign in question ran during major sporting events broadcast globally and appeared on TikTok and Facebook, according to Novo Nordisk's complaint.
Eli Lilly defended its marketing approach, stating that its claims rest on Surmount-5, described as the only head-to-head randomized clinical trial directly comparing tirzepatide (Eli Lilly's molecule) and semaglutide (Novo Nordisk's molecule) for weight management.
"Rather than competing on the merits of its products, Novo is asking a court to prevent Lilly from communicating the results of this trial," an Eli Lilly spokesperson said. "We firmly stand by our advertising campaign."
Both drugs belong to a class of treatments that mimic GLP-1, a hormone produced by the intestines. These medications are used for weight loss and to treat type 2 diabetes. The anti-obesity drug market has become a major revenue driver for both companies as demand for these treatments has surged in recent years.
Author James Rodriguez: "This lawsuit reveals the intense pressure these pharma giants face to dominate a lucrative market, but courts shouldn't have to referee marketing wars over which obesity drug works better when both are already life-changing for patients."
Comments